Search Result

Isoforms Recommended:	Metallo-β-lactamase

Results for "

metallo-β-lactamase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Beta-lactamase (30) Angiotensin-converting Enzyme (ACE) (4) Antibiotic (1) Apoptosis (8) Autophagy (3) Bacterial (26) Bcl-2 Family (1) CFTR (2) Complement System (1) Endogenous Metabolite (2) HDAC (9) iGluR (2) Isotope-Labeled Compounds (1) Melanocortin Receptor (5) Parasite (1) Phospholipase (1) Proteasome (1) Virus Protease (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (6) Endocrinology (1) Infection (32) Inflammation/Immunology (5) Metabolic Disease (5) Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Beta-lactamase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-168500

Metallo-β-lactamase-IN-16	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-16 (compound 18) is a sulfone containing *metallo-β-lactamase* inhibitor with an anti-bacterial activity. Metallo-β-lactamase-IN-16 inhibits NDM-1 (New Dehli metallo-β-lactamase-1), IMP-1 (imipenemase-1), VIM-1 (Verona integron-encoded metallo-β-lactamase), and VIM-2 with IC₅₀ values of 0.16 nM, 0.23 nM, 0.31 nM and 1.0 nM, respectively .

HY-143415

Metallo-β-lactamase-IN-7	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-7 is a potent VIM-Type metallo-β-lactamase inhibitor with IC₅₀s of 0.019 μM, 13.64 μM, 0.38 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-7 potentiate antibacterial activity of Meropenem against the Gram-negative bacterial strains .

HY-163338

Metallo-β-lactamase-IN-13	Beta-lactamase	Infection
Metallo-β-lactamase-IN-13 (Compound 13i) is a pan *Metallo-β-Lactamase* inhibitor. Metallo-β-lactamase-IN-13 provides broader coverage of metallo-β-lactamases expressing Gram-negative (GN) bacteria. Metallo-β-lactamase-IN-13 has antibacterial activity against P. aeruginosa .

HY-143414

Metallo-β-lactamase-IN-6	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-6 is a potent VIM-Type *metallo-β-lactamase* inhibitor with IC₅₀s of 0.56 μM, 29.50 μM and 5.78 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-6 displays potent synergistic antibacterial activity with Meropenem against engineered Escherichia coli strains and intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL .

HY-163339

Metallo-β-lactamase-IN-14	Beta-lactamase	Infection
Metallo-β-lactamase-IN-14 (Compound 17e) is a *Metallo-β-Lactamase* inhibitor. Metallo-β-lactamase-IN-14 shows inhibition activity against VIM-1 and VIM-2. Metallo-β-lactamase-IN-14 has antibacterial activity against Gram-negative (GN) bacteria and P. aeruginosa .

HY-146165

Metallo-β-lactamase-IN-8	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-8 (compound 17) is a potent, reversible and competitive broad-spectrum inhibitor of metallo-β-lactamases (MβLs), with IC₅₀s of 1.3 μM, 5.7 μM, 9.8 μM, and 9.9 μM for L1, ImiS, IMP-1 and VIM-2, respectively. Metallo-β-lactamase-IN-8 exhibits antibacterial activity .

HY-161094

Metallo-β-lactamase-IN-12	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-12 is a dual inhibitor of metal β-lactamases (MβLs (NDM-1, IMP-1)) and *serine β-lactamases* (SβLs (OXA-48, KPC-2)), with IC₅₀** values of 0.64 μM, 1.32 μM, 1.01 μM, and 0.57 μM, respectively. Metallo-β-lactamase-IN-12 has antibacterial activity .

HY-144659

Metallo-β-lactamase-IN-5	Beta-lactamase Apoptosis Bacterial	Infection
Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC₅₀ of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity .

HY-144261

Metallo-β-lactamase-IN-3	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-3 (compound 35) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-3 shows high activity against VIM-1 and NDM-1, with IC₅₀ of 0.6 and 1.0 μM, respectively. Metallo-β-lactamase-IN-3 does not show inhibition of IMP-7 .

HY-155504

Metallo-β-lactamase-IN-11	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-11 (compound 5f) is a *Metallo-β-lactamases* (MBLs) inhibitor, potent against bacterial metallophyllactamase CphA (IC₅₀=45 µM). Metallo-β-lactamase-IN-11 (10 µM) inhibits NDM-1 by 49% and AIM-1 by 61%. Metallo-β-lactamase-IN-11 can be used in the research of inhibiting antibiotic resistance .

HY-152105

Metallo-β-lactamase-IN-9	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-9 (Compound 23) is a pan metallo-beta-lactamase (MBL) inhibitor with IC₅₀s of 35, 269 and 369 nM against NDM-1, VIM-1 and IMP-1, respectively .

HY-144259

Metallo-β-lactamase-IN-2	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC₅₀ values of 0.1 μM (VIM-1), 1.3 μM (NDM-1), and 5.0 μM (IMP-7), respectively .

HY-144262

Metallo-β-lactamase-IN-4	Beta-lactamase Bacterial	Infection
Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC₅₀ values of 0.5 μM (VIM-1), 2.1 μM (NDM-1), and 3.3 μM (IMP-7), respectively .

HY-161310

Metallo-β-lactamase-IN-15	Beta-lactamase	Infection
Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC₅₀ values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively .

HY-136306

Metallo β-lactamase ligand 1	Beta-lactamase Bacterial	Infection
Metallo-beta-lactamase ligand 1 is a class B *β-lactamase* inhibitor with antibacterial activity extracted from patent WO2019221122A1, compound A .

HY-149929

EBL-3183	Beta-lactamase Bacterial	Infection
EBL-3183, an indole-2-carboxylate, is a potent metallo-β-lactamase (MBL) inhibitor. EBL-3183 is reversibly binding, non-covalent, competitive NDM-1 inhibitor with a pIC₅₀ of 7.7 .

HY-155202

YJ196	Others	Others
YJ196 (Compound 59) is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor .

HY-12826

IMB-XH1	Beta-lactamase Bcl-2 Family Bacterial	Cancer
IMB-XH1 is an inhibitor of myeloid cell factor 1 (Mcl-1) . IMB-XH1 is a non-competitive Delhi metallo-β-lactamase (NDM-1) inhibitor. The IC₅₀s of IMB-XH1 against metallo-β-lactamases NDM-1, IMP-4, ImiS and L1 are 0.4637 μM, 3.980 μM, 0.2287 μM and 1.158 μM, respectively .

HY-117951

ANT431	Beta-lactamase	Infection
ANT431 is a metallo-β-lactamase inhibitor that also restores the effectiveness of Meropenem (HY-13678) in a mouse thigh Escherichia coli infection model .

HY-146637

VIM-2-IN-1	Beta-lactamase Bacterial	Infection
VIM-2-IN-1 (compound 1dj) is a *β-lactamase* inhibitor with antibacterial activities. VIM-2-IN-1 has moderate IC₅₀ values of 23 µM, 48 µM and 231 µM for *Verona integron-encoded metallo-β-lactamase* (VIM-2), German imipenemase-1 (GIM-1) and New Delhi metallo-β-lactamase (NDM-1)**, respectively .

HY-162174

MBL-IN-2	Beta-lactamase Bacterial	Infection
MBL-IN-2 ((2R, 2R')-5αC) is an inhibitor of Metallo-β-lactamase (MBL) that can inhibit *New Delhi Metallo-β-lactamase-1 (NDM-1)* with an IC₅₀ of 0.3 μM. MBL-IN-2 ((2R, 2R')-5αC) can be used for the study of resistance to β-lactam antibiotics .

HY-150758

NDM-1 inhibitor-3	Beta-lactamase Bacterial	Infection
NDM-1 inhibitor-3 (Compound 89) is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor with a K_i of 4 μM .

HY-155283

Zndm19	Beta-lactamase Bacterial	Infection
Zndm19 is a *New Delhi Metallo-β-lactamase-1 (NDM-1)* inhibitor. Zndm19 can be used for the research of drug-resistant bacterial infections .

HY-100871

WT-161 5+ Cited Publications	Beta-lactamase HDAC Apoptosis	Cancer
WT-161 is a potent and selective HDAC6 inhibitor with an IC₅₀ of 0.40 nM . WT-161 also inhibits metallo-β-lactamase domain-containing protein?2 (MBLAC2) .

HY-13428

Tubacin 10+ Cited Publications	Beta-lactamase HDAC Virus Protease	Cancer
Tubacin is a potent and selective inhibitor of HDAC6, with an IC₅₀ value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-19328

ACY-775 2 Publications Verification	HDAC	Cardiovascular Disease Neurological Disease
ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC₅₀ of 7.5 nM . ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .

HY-10990

Abexinostat 5+ Cited Publications CRA 024781; PCI-24781	HDAC	Cancer
Abexinostat (CRA 024781) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with K_i of 7 nM. Abexinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ below 10 nM .

HY-13322

Pracinostat 5+ Cited Publications SB939	Beta-lactamase HDAC Apoptosis	Cancer
Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC₅₀s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ below 10 nM .

HY-105246

Pracinostat dihydrochloride	Beta-lactamase HDAC Apoptosis	Cancer
Pracinostat dihydrochloride is a potent histone deacetylase (HDAC) inhibitor, with IC₅₀s of 40-140 nM, used for cancer research. Pracinostat dihydrochloride also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ below 10 nM .

HY-144100

*β-Lactamase-IN-7*	Beta-lactamase Bacterial	Infection
β-Lactamase-IN-7 (compound 14) is a potent VIM-Type metallo-β-lactamase inhibitor, with K_is of 1.26 μM and 0.54 μM for VIM-1 and VIM-4, respectively. β-Lactamase-IN-7 can effectively inhibit Klebsiella pneumoniae .

HY-13271

Tubastatin A Hydrochloride Maximum Cited Publications 24 Publications Verification Tubastatin A HCl; TSA HCl	Beta-lactamase HDAC Autophagy Apoptosis	Cancer
Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective HDAC6 inhibitor with IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-13271A

Tubastatin A Maximum Cited Publications 24 Publications Verification	Beta-lactamase HDAC Autophagy Apoptosis	Cancer
Tubastatin A is a potent and selective HDAC6 inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-13271B

Tubastatin A TFA TSA TFA	HDAC Autophagy Apoptosis	Cancer
Tubastatin A (TSA) TFA is a potent and selective?HDAC6?inhibitor with?IC₅₀?of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A TFA also inhibits HDAC10 and metallo-β-lactamase domain-containing protein?2 (MBLAC2).

HY-B0368

Captopril 15+ Cited Publications SQ 14225	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Cancer
Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC₅₀=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC₅₀ of 7.9 μM .

HY-B0368A

Captopril hydrochloride SQ 14225 hydrochloride	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Captopril (SQ 14225) hydrochloride, antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC₅₀=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril hydrochloride is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC₅₀ of 7.9 μM .

HY-162493

MBL-IN-3	Bacterial	Infection
MBL-IN-3 (compound 72922413) is a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor(IC₅₀=54±4 μM). MBL-IN-3 is identified and shown to lower minimum inhibitory concentrations (MICs) of Meropenem (HY-13678) for a panel of E. coli and K. pneumoniae clinical isolates expressing NDM-1. MBL-IN-3 can be used for antibiotic sensitizer research .

HY-B0368S

Captopril-d3 SQ 14225-d₃	Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Captopril-d₃ is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM[1][2][3].

HY-B0368R

Captopril (Standard)	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Cancer
Captopril (Standard) is the analytical standard of Captopril. This product is intended for research and analytical applications. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .

HY-118013

NDM-1 inhibitor-2	Others	Infection
NDM-1 inhibitor-2 is an inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1) and has the ability to inhibit NDM-1 activity. NDM-1 inhibitor-2 exhibits a good inhibitory effect on drug-resistant bacterial strains that overexpress NDM-1. When NDM-1 inhibitor-2 is used in combination with the carbapenem antibiotic meropenem, a favorable synergistic effect can be produced .

HY-113590

FR295389	Bacterial	Infection
FR295389 is a dihydroimidazopyrazolium cephalosporin with antibacterial activity. FR295389 shows activity against IMP-type metallo-β-lactamases (MBL)-producing Klebsiella pneumoniae, Acinetobacter baumanii and Pseudomonas putida with MIC values ranging from 4 to 32 mg/mL .

HY-121765

Dacisteine N,S-Diacetyl-L-cysteine	Endogenous Metabolite	Metabolic Disease
Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less *New Delhi metallo-beta-lactamase-1 (NDM-1)* inhibitor with an IC₅₀ value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .

HY-148493

MK-3402	Bacterial	Infection
MK-3402 (Compound303) is a metallo-beta-lactamase inhibitor, with IC₅₀ values of 0.53, 0.25 and 0.169 nM against IMP-1, NDM-1, and VIM-1, respectively. MK-3402 can be used in bacterial research and shows a synergistic effect when used in combination with beta-lactam antibiotics .

HY-121765R

Dacisteine (Standard) N,S-Diacetyl-L-cysteine (Standard)	Endogenous Metabolite	Metabolic Disease
Dacisteine (Standard) is the analytical standard of Dacisteine. This product is intended for research and analytical applications. Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less *New Delhi metallo-beta-lactamase-1 (NDM-1)* inhibitor with an IC₅₀ value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .

HY-129200

Aspergillomarasmine A	Others	Others
Aspergillomarasmine A is a natural aminopolycarboxylic acid with potent inhibitory activity against class B metallo-β-lactamases (MBLs). Aspergillomarasmine A inactivates MBLs by removing a catalytic Zn2+ cofactor. Aspergillomarasmine A acts as a selective Zn2+ scavenger, promoting the dissociation of the metal cofactor, thereby indirectly inactivating NDM-1. Aspergillomarasmine A causes the loss of Zn2+ ions from the low-affinity binding site of NDM-1. The action of Aspergillomarasmine A results in the rapid degradation of Zn2+-deficient NDM-1, thereby enhancing its potency as a β-lactam enhancer. The mechanism of Aspergillomarasmine A has broad applicability among different Zn2+ chelators .

HY-155104

MBL-IN-1	Beta-lactamase Bacterial	Infection
MBL-IN-1 (compound 41) is a *β-Lactamase* inhibitor, with the IC₅₀ ranging from 0.10 to 25.85 µM. MBL-IN-1 can be used for research of bacterial infections .

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P2064

Lariatin A	Bacterial	Infection
Lariatins is a novel anti-mycobacterial peptides with a lasso structure produced by Rhodococcus jostii K01-B0171 .

HY-P3100

Orfamide A	Parasite	Infection
Orfamide A is a major metabolite of insecticidal biosurfactant in Pseudomonas sp. F6 and has aphidicidal activity. Orfamide A can be used for aphid control in organic agriculture. Orfamide A exhibits dose-dependent mortality against aphids with an LC₅₀ value of 34.5 μg/mL .

HY-106178

PMX-53 4 Publications Verification 3D53	Complement System	Cardiovascular Disease Inflammation/Immunology Cancer
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC₅₀ of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .

Cat. No.	Product Name	Target	Research Area

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P0267

Melanotan (MT)-II	Peptides	Neurological Disease
Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is an injectable peptide hormone used to promote tanning.

HY-106178

PMX-53 4 Publications Verification 3D53	Complement System	Cardiovascular Disease Inflammation/Immunology Cancer
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC₅₀ of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .

HY-P10278

Anantin	Peptides	Endocrinology
Anantin binds competitively to the receptor of atrial natriuretic factor (ANF) from bovine adrenal cortex (K_d = 0.6 μM) and acts as natriuretic peptide receptor A antagonist .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P2064

Lariatin A	Bacterial	Infection
Lariatins is a novel anti-mycobacterial peptides with a lasso structure produced by Rhodococcus jostii K01-B0171 .

HY-P0007

Elcatonin Carbocalcitonin	Peptides	Metabolic Disease
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .

HY-P2120

Pseudobactin A	Peptides	Others
Pseudobactin A is a non-fluorescent extracellular iron carrier produced by the plant growth-promoting bacterium Pseudomonas B10 .

HY-P3100

Orfamide A	Parasite	Infection
Orfamide A is a major metabolite of insecticidal biosurfactant in Pseudomonas sp. F6 and has aphidicidal activity. Orfamide A can be used for aphid control in organic agriculture. Orfamide A exhibits dose-dependent mortality against aphids with an LC₅₀ value of 34.5 μg/mL .

HY-P2123A

Colistin A sulfate hydrate	Bacterial Antibiotic	Infection
Colistin A sulfate hydrate is a major component of Colistin. Colistin is a polymyxin antibiotic and can be used to combat infections caused by problematic gram-negative bacteria .

HY-P1208

PG-931	Melanocortin Receptor	Inflammation/Immunology
PG-931, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC₅₀=0.58 nM) agonist and is more selective than for the hMC3R (IC₅₀=55 nM) or the hMC5R (IC₅₀=2.4 nM). PG-931 can reverse haemorrhagic shock and prevent multiple organ damage in vivo .

HY-P1208A

PG-931 TFA	Melanocortin Receptor	Inflammation/Immunology
PG-931 TFA, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC₅₀=0.58 nM) agonist and is more selective than for the hMC3R (IC₅₀=55 nM) or the hMC5R(IC₅₀=2.4 nM). PG-931 TFA can reverse haemorrhagic shock and prevent multiple organ damage in vivo .

HY-P1193

GR 82334	Peptides	Neurological Disease
GR 82334 is a potent and specific reversible tachykinin NK1 receptor antagonist . GR 82334 inhibits substance P-induced sensitization by blocking SP NK1 receptors in naked mole-rats .

HY-P0227

SHU 9119 2 Publications Verification	Melanocortin Receptor	Metabolic Disease
SHU 9119 is a potent human melanocortin 3 and 4 receptors (MC3/4R) antagonist and a partial MC5R agonist; with IC₅₀ values of 0.23, 0.06, and 0.09 nM for human MC3R, MC4R and MC5R, respectively.

HY-P1209A

PG106 TFA	Melanocortin Receptor	Metabolic Disease
PG106 TFA is a potent and selective human melanocortin 3 (hMC3) receptor antagonist (IC₅₀= 210 nM) and has noactivity at hMC4 receptors (EC₅₀=9900 nM) and hMC5 receptor .

HY-P1209

PG106	Melanocortin Receptor	Inflammation/Immunology
PG106 is a potent and selective human melanocortin 3 (hMC3) receptor antagonist (IC₅₀=210 nM) and has noactivity at hMC4 receptors (EC₅₀=9900 nM) and hMC5 receptor .

HY-P4910

Baceridin	Proteasome Apoptosis	Cancer
Baceridin is a proteasome inhibitor and a cyclic hexapeptide. Baceridin can be isolated from the culture medium of Epiphytic Bacillus. Baceridin can inhibit cell cycle progression and induce tumor cell apoptosis through a p53-independent pathway. Baceridin can be used in cancer research .

HY-P5568

RP 71955	Peptides	Infection
RP 71955 is an antimicrobial peptide against HIV-1 .

HY-P2202

Desferriferribactin	Bacterial	Others
Desferriferribactin is a cyclic peptide containing a thirteen-membered ring. Desferriferribactin is a precursor of pyoverdins .

HY-P10447

Plipastatin A1 Fengycin IX; SNA-60-367-3	Phospholipase	Inflammation/Immunology
Plipastatin A1 is a lipopeptide with enzyme inhibitory and immunosuppressive activities. Plipastatin A1 is found in Bacillus cereus and inhibits phospholipase A2 (PLA2), PLC, and PLD .

HY-P1108

Astressin 2B	CFTR	Others
Astressin 2B is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC₅₀ values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B antagonizes CRF2-mediated inhibition of gastric emptying .

HY-P1108A

Astressin 2B TFA	CFTR	Others
Astressin 2B TFA is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC₅₀ values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B TFA antagonizes CRF2-mediated inhibition of gastric emptying .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-121765

Dacisteine N,S-Diacetyl-L-cysteine	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less *New Delhi metallo-beta-lactamase-1 (NDM-1)* inhibitor with an IC₅₀ value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .

HY-121765R

Dacisteine (Standard) N,S-Diacetyl-L-cysteine (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Endogenous Metabolite
Dacisteine (Standard) is the analytical standard of Dacisteine. This product is intended for research and analytical applications. Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less *New Delhi metallo-beta-lactamase-1 (NDM-1)* inhibitor with an IC₅₀ value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .

HY-129200

Aspergillomarasmine A	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Others
Aspergillomarasmine A is a natural aminopolycarboxylic acid with potent inhibitory activity against class B metallo-β-lactamases (MBLs). Aspergillomarasmine A inactivates MBLs by removing a catalytic Zn2+ cofactor. Aspergillomarasmine A acts as a selective Zn2+ scavenger, promoting the dissociation of the metal cofactor, thereby indirectly inactivating NDM-1. Aspergillomarasmine A causes the loss of Zn2+ ions from the low-affinity binding site of NDM-1. The action of Aspergillomarasmine A results in the rapid degradation of Zn2+-deficient NDM-1, thereby enhancing its potency as a β-lactam enhancer. The mechanism of Aspergillomarasmine A has broad applicability among different Zn2+ chelators .

Cat. No.	Product Name	Chemical Structure

HY-B0368S

Captopril-d3
Captopril-d₃ is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

metallo-β-lactamase

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products